# PCSK9 Inhibitors in the Progression of Aortic Stenosis

Study · id `cardio:ct-nct03051360` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03051360](<https://clinicaltrials.gov/study/NCT03051360>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03051360

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT03051360. Randomized; quadruple masking; primary purpose prevention. Start 2017-06-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT03051360, source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)
- Planned start: 2017-06-01 (anticipated) (ClinicalTrials.gov record NCT03051360, source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03051360, source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)
- Completion: 2020-01-01 (anticipated) (ClinicalTrials.gov record NCT03051360, source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03051360, source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03051360-2017-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: PCSK9 Inhibitors in the Progression of Aortic Stenosis
- Condition: Aortic Valve Stenosis
- Intervention (Drug): PCSK9 Inhibitor \[EPC\]
- Intervention (Drug): Placebos
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)

## Provenance

Content hash: 79a879e80445c7f0122b4f82c7d8e6bf4c0b03ba42124027b4d06f55bd0e4ebd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
